Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Press Releases Year None2023202220212020 May 11, 2023 Invivyd Reports First Quarter 2023 Financial Results and Business Highlights May 04, 2023 Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights Apr 25, 2023 Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference Apr 25, 2023 Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update Apr 12, 2023 Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer Mar 30, 2023 Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19 Mar 23, 2023 Invivyd Reports Full Year 2022 Financial Results and Business Highlights Mar 22, 2023 Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19 Mar 16, 2023 Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights Mar 06, 2023 Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
Year None2023202220212020 May 11, 2023 Invivyd Reports First Quarter 2023 Financial Results and Business Highlights May 04, 2023 Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights Apr 25, 2023 Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference Apr 25, 2023 Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update Apr 12, 2023 Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer Mar 30, 2023 Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19 Mar 23, 2023 Invivyd Reports Full Year 2022 Financial Results and Business Highlights Mar 22, 2023 Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19 Mar 16, 2023 Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights Mar 06, 2023 Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
May 04, 2023 Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
Apr 25, 2023 Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
Apr 12, 2023 Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
Mar 30, 2023 Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
Mar 22, 2023 Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
Mar 16, 2023 Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
Mar 06, 2023 Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies
